Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDE-etoposide
- Development stage
- Unknown
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LDE-etoposide is a lipid-based nanoformulation of etoposide that utilizes a lipid nanoemulsion delivery system. The LDE particle mimics the structure of low-density lipoprotein (LDL) and is designed to target cancer cells that overexpress LDL receptors. This formulation aims to improve the therapeutic index of etoposide by enhancing tumor cell uptake while reducing systemic toxicity. The etoposide component works by inhibiting DNA topoisomerase II, preventing DNA re-ligation and leading to cell cycle arrest and apoptosis in cancer cells.
- Other names
- lipid nanoemulsion etoposideLDE etoposide
02
Targets
TOP2A (DNA topoisomerase II)LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on LDE-etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDE-etoposide.